Comparative Pharmacology
Head-to-head clinical analysis: HI COR versus TRIACET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HI COR versus TRIACET.
HI-COR vs TRIACET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin and leukotriene synthesis.
Triacetin is a triester of glycerol and acetic acid. Its exact mechanism of action is not fully understood, but it exhibits antifungal activity by disrupting fungal cell membrane integrity and inhibiting fungal growth.
0.1-0.2 mg/kg intravenously once.
0.5-1 mg orally three times daily; maximum dose 4 mg/day.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours. Clinical context: Short half-life requires frequent dosing for sustained effect; accumulation possible in renal impairment.
Terminal elimination half-life is approximately 3.5–4 hours in adults with normal renal function; may be prolonged (up to 6–8 hours) in patients with hepatic impairment.
Renal excretion of unchanged drug and metabolites accounts for approximately 70-80% of elimination, with biliary/fecal excretion contributing 20-30%.
Renal, unchanged drug: <1% of dose; metabolites: approximately 20% in urine, remainder in feces via biliary elimination.
Category C
Category C
Corticosteroid
Corticosteroid